Eye drops composition containing stem cell exosomes and preparation method thereof

By adding prostaglandin E2 and IL-4 to mesenchymal stem cell culture medium and adding lipopolysaccharides under certain conditions, optimized exosomes were prepared for eye drops, and dry eye diseases in the prior art were solved and The problem of poor treatment effect of fatigue significantly improves the treatment effect.

CN118453656BActive Publication Date: 2024-11-22BEIJING SINOMENIUM STEM CELL TECH RES INST CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410910722.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-09
Publication Date
2024-11-22
Estimated Expiration
2044-07-09

AI Technical Summary

Technical Problem

Existing eye drops containing mesenchymal stem cell-derived exosomes have limited effects in treating dry eye syndrome and relieving visual fatigue, and their therapeutic effects need to be improved.

Method used

Optimized exosomes were prepared by adding prostaglandin E2 and IL-4 to mesenchymal stem cell culture medium and adding lipopolysaccharides under certain conditions, and combined with pharmaceutically acceptable carriers to prepare eye drops for use in the Treat dry eye and visual fatigue.

Benefits of technology

It significantly improves the therapeutic effect of dry eye disease and the ability to relieve visual fatigue, enhances tear secretion, tear film stability, goblet cell recovery and intraocular pressure regulation, especially through short-term lipopolysaccharide stimulation, and is more effective.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118453656B_ABST
    Figure CN118453656B_ABST
Patent Text Reader

Abstract

The present invention provides an eye drop composition containing stem cell exosomes, including exosomes from mesenchymal stem cells and a pharmaceutically acceptable carrier, wherein the exosomes are prepared by the following steps: 1) culturing the mesenchymal stem cells in a medium containing prostaglandin E2 and IL-4 until the cell confluence reaches 80-90%, and then performing cell passage inoculation; 2) continuing to culture the mesenchymal stem cells after passage, collecting the culture supernatant when the cell confluence is 60-70%, and separating the exosomes from the culture supernatant. The eye drop composition provided herein can be used for the treatment of dry eye, and can also be used for the relief of visual fatigue.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an eye drop composition, in particular to an eye drop composition containing exosomes derived from mesenchymal stem cells, and also relates to a preparation method of the eye drop composition. Background Art

[0002] Eyes are the most important organ of human senses. About 80% of the knowledge in the brain is acquired through the eyes. In recent years, the main way for people to obtain information has shifted from traditional paper reading to various electronic screens, especially computers and mobile phones. This way of using eyes can easily cause visual fatigue, including dry eyes, sore eyes, soreness and congestion, and increased intraocular pressure.

[0003] Exosomes from mesenchymal stem cells have been reported to have therapeutic effects on dry eye, for example, Chinese patent publications CN115337325A, CN109431985A, CN109419770A, etc., but there is still a need to improve their therapeutic effects. Summary of the invention

[0004] In one aspect, the present invention provides an eye drop composition containing stem cell exosomes, comprising exosomes from mesenchymal stem cells and a pharmaceutically acceptable carrier, wherein the exosomes are prepared by the following steps:

[0005] 1) culturing the mesenchymal stem cells in a culture medium containing prostaglandin E2 and IL-4 until the cell confluence reaches 80-90%, and then performing cell subculture inoculation;

[0006] 2) continuing to culture the mesenchymal stem cells after passage, collecting the culture supernatant when the cell confluence is 60-70%, and isolating the exosomes from the culture supernatant.

[0007] In some embodiments, the mesenchymal stem cells are human bone marrow mesenchymal stem cells.

[0008] In some embodiments, lipopolysaccharide is further added to the culture medium during the first two days of cell culture in step 1).

[0009] In some embodiments, the culture medium does not contain prostaglandin E2 and IL-4 during the first two days of cell culture in step 1).

[0010] In some embodiments, the concentration of prostaglandin E2 in the culture medium is 0.1-1 μM, the concentration of IL-4 in the culture medium is 20-60 nM, and the concentration of lipopolysaccharide in the culture medium is 10-200 nM.

[0011] In some embodiments, the eye drop composition comprises: 5 mg / L of the exosomes, 2 g / L vitamin E and 2 g / L sodium hyaluronate, wherein the concentration of the exosomes is based on the protein concentration determined by the BrandFord method.

[0012] In another aspect, the present invention provides a method for preparing an eye drop composition, comprising:

[0013] 1) Cultivate mesenchymal stem cells in a medium containing prostaglandin E2 and IL-4 until the cell confluence reaches 80-90%, then perform cell subculture;

[0014] 2) continuing to culture the mesenchymal stem cells after passage, collecting the culture supernatant when the cell confluence is 60-70%, and isolating the exosomes from the culture supernatant; and

[0015] 3) mixing the exosomes with a pharmaceutically acceptable carrier.

[0016] In some embodiments, lipopolysaccharide is further added to the culture medium during the first two days of cell culture in step 1).

[0017] In some embodiments, the culture medium does not contain prostaglandin E2 and IL-4 during the first two days of cell culture in step 1).

[0018] In some embodiments, the concentration of prostaglandin E2 in the culture medium is 0.1-1 μM, the concentration of IL-4 in the culture medium is 20-60 nM, and the concentration of lipopolysaccharide in the culture medium is 10-200 nM.

[0019] The eye drop composition provided herein can be used for the treatment of dry eye syndrome and can also be used for the relief of visual fatigue. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The results of tear secretion detection experiments in mice are shown. Only the significant differences between the groups of interest are shown. Refers to p < 0.05.

[0021] Figure 2 The tear film breakup time results in mice are shown. Only the significant differences between the groups of interest are shown. Refers to p < 0.05; Refers to p < 0.01.

[0022] Figure 3 The results of goblet cell counts in mice are shown. Only significant differences between groups of interest are shown. Refers to p < 0.05; Refers to p < 0.01.

[0023] Figure 4 Shows the intraocular pressure change curve in the black-eyed rabbit experiment.

[0024] Figure 5 Shown are the results of ciliary cAMP and cGMP levels measured in the black-eyed rabbit experiment. DETAILED DESCRIPTION

[0025] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0026] The present inventors have found in their research that adding prostaglandins PGE2 and IL-4 to the mesenchymal stem cell culture medium can enhance the effect of the prepared exosomes in treating dry eye and relieving eye fatigue, and further adding lipopolysaccharide (LPS) can further enhance the effect.

[0027] The present invention is described below by means of specific examples.

[0028] Example 1 Mesenchymal stem cell culture and exosome preparation

[0029] Human bone marrow-derived mesenchymal stem cells (PT-2501, Lonza) were cultured at 3 x 10 4 Cells / cm 2 The cells were inoculated at a density of 100 μg / mL in a T-75 cell culture flask and cultured in an incubator at 37°C and 5% CO2 using MSCGM-CD™ medium (hereinafter referred to as the first generation culture). When the cell confluence reached 80-90%, the cells were digested with 0.25% trypsin and then passaged at the same cell density. The cells were cultured in the same medium and conditions (hereinafter referred to as the second generation culture) for about 3 days (when the cell confluence was about 60-70%), and the supernatant was collected. At 4°C, 100 mL of the collected supernatant was centrifuged at 800 g for 10 minutes to collect the supernatant; the supernatant was centrifuged at 2,000 g for 10 minutes to collect the supernatant; the supernatant was centrifuged at 15,000 g for 30 minutes to collect the supernatant; the supernatant was centrifuged at 150,000 g for 30 minutes to collect the precipitate, which was resuspended in 20 mL of PBS buffer; the precipitate was centrifuged at 150,000 g for 30 minutes to collect the precipitate, which was resuspended in 2 mL of PBS buffer to obtain mesenchymal stem cell-derived exosomes. Scanning electron microscopy showed that the particles were roughly round or oval, with a diameter of about 50 to 150 nm. Western blotting confirmed that the prepared exosomes expressed transmembrane proteins CD9, CD63, and CD81, but did not express protein Calnexin. The exosome concentration was determined by the BrandFord method.

[0030] The exosomes prepared in the above manner were used as control exosomes. Experimental exosomes A, B, and C were prepared in the same manner:

[0031] Experimental exosome A: The difference from the above control exosome preparation method is that 0.5 μg / mL prostaglandin E2 (PGE2) and 40 ng / mL mouse IL-4 were added to the culture medium during the first generation culture.

[0032] Experimental exosome B: The difference from the preparation method of exosome A is that 50 ng / mL lipopolysaccharide (LPS) was added to the culture medium during the first two days of the first generation culture, and then replaced with a culture medium without LPS (still containing 0.5 μg / mL PGE2 and 40 ng / mL mouse IL-4).

[0033] Experimental exosome C: The difference from the preparation method of exosome A is that 50 ng / mL lipopolysaccharide (LPS) was added to the culture medium during the first two days of the first generation culture, without PGE2 and mouse IL-4, and then replaced with a culture medium containing 1 μg / mL PGE2 and 40 ng / mL mouse IL-4.

[0034] The prepared exosomes were stored at -80°C after aliquoting.

[0035] Example 2 Animal Experiment

[0036] 2.1 Mouse experiments

[0037] The dry eye model was established using 6-8 week old BALB / c mice according to the method of Lin et al. (Liu, X, et al .,(2011). A mouse dry eye model induced by topical administration of benzalkonium chloride. Molecular vision , 17, 257-264). Briefly, 2 g / L benzalkonium chloride was dripped into both eyes of mice twice a day for two weeks. A total of 42 mice were randomly selected to construct the model, and the remaining 7 mice were not treated and used as negative controls.

[0038] Eye drops were prepared with the following component concentrations: 5 mg / L exosomes, 2 g / L vitamin E, 2 g / L sodium hyaluronate, and the remainder was medical saline.

[0039] After the mouse modeling was completed, 35 modeled mice were randomly divided into five groups. Four of the groups were treated with eye drops containing control exosomes, experimental exosomes A, B or C three times a day, 10 μL / eye each time, for 10 days. The other group was not treated as a positive control, and then tear secretion test (SchirmerⅠtest, SIT) and tear film break-up time test (tearbreak-uptime, BUT) were performed.

[0040] SIT experiment: Place one end of a phenol red cotton thread at the middle and outer third of the outer canthus of the mouse eye, remove it after 60 seconds, and measure the length of the red part of the phenol red cotton thread. Both eyes of each mouse were measured.

[0041] BUT experiment (conducted one day after SIT experiment): 10 μL of sodium fluorescein (1%) eye drops were dripped into the conjunctival sac of mice. After blinking, the time of the first rupture point in the corneal staining area was observed and recorded under cobalt blue light of a slit lamp microscope. Both eyes of each mouse were measured. The smaller the BUT value, the worse the tear film stability.

[0042] The results of SIT experiment and BUT experiment are shown in Figure 1 and Figure 2 The results show that the addition of PGE2 and IL-4 enhances the therapeutic effect of mesenchymal stem cell-derived exosomes on dry eye, and the addition of LPS further enhances this effect. It is worth noting that the addition of LPS together with PGE2 and IL-4 in the culture medium until passage did not enhance the therapeutic effect, indicating that LPS has a better short-term stimulation effect. This can also be reflected in the fact that the effect of exosome C is better than that of exosome B.

[0043] After the SIT and BUT experiments, the mice were killed by cervical dislocation, and one eyeball was randomly removed from each mouse. The slices were made and stained with periodic acid-Schiff (PAS) reagent. The cells with dark red cytoplasm were conjunctival goblet cells. The conjunctival goblet cells of the mice were counted under a microscope, and the average value of 6 slices at different equal positions was taken for each eye. The results are shown in Figure 3 Basically consistent with the results of the above SIT experiment, the use of PGE2 and LPS enhanced the goblet cell recovery effect of mesenchymal stem cell-derived exosomes.

[0044] 2.2 Black-eyed rabbit experiment

[0045] 40 black-eyed rabbits (half male and half female) weighing 2-2.5 kg were provided by the Experimental Animal Center of Zhejiang Chinese Medical University. The animal model of visual fatigue was established by 30 lux illumination during the day and 0 lux at night for 6 days.

[0046] After the model was constructed, the animals were randomly divided into 4 groups (half male and half female), and the eye drops containing control exosomes, experimental exosomes A, B or C were applied to the eyes 3 times a day, 50 μL / eye each time, for 7 days. The intraocular pressure (IOP) was measured by the American Raycus Tono-Pen™-XL tonometer 2 hours after the last administration of the day. The IOP value (average of each group) change curve is shown in Figure 4The results showed that compared with the control exosome group, the experimental groups had better effects and lowered blood pressure faster, especially the exosomes B and C groups, which had basically reduced intraocular pressure to normal levels on the third day.

[0047] After the intraocular pressure measurement, the animals were killed, the experimental eyes were removed, the ciliary bodies were separated under a microscope, washed and homogenized, and centrifuged at 2000g for 10 minutes. The supernatant was taken and the cAMP and cGMP contents were determined by ELISA kit. The results of cAMP and cGMP contents are shown in Figure 5 The cAMP and cGMP levels can reflect the fatigue state of the ciliary muscles. When the eyes are overused, the ciliary muscles remain tense, the cAMP level decreases, and the cGMP level increases. Figure 5 The results showed that the exosomes B and C group eye drops were superior to the control exosome eye drops in restoring cAMP levels, with significant differences (p<0.05); the exosomes A, B and C groups were superior to the control exosomes in reducing cGMP levels, with significant differences (p<0.05).

[0048] Based on the above experimental results, the eye drops containing exosomes A, B or C prepared by the present invention are superior to exosomes derived from ordinary mesenchymal stem cells in the ability to treat dry eye and relieve visual fatigue.

[0049] Example 3 PGE2, IL-4 and LPS concentration selection

[0050] PGE2 has little effect on the above experimental results within the concentration range of 0.1-1μM. At higher concentrations, it can affect the production of exosomes. For example, at a concentration of 5μM, the production of exosomes can be reduced by about 10%. At a concentration of 0.05μM, there was still a significant difference from the control exosomes in the mouse experiment (p< 0.05), but there was no significant difference from the control exosomes in lowering intraocular pressure and restoring cAMP levels in the black-eyed rabbit experiment (p> 0.05).

[0051] The IL-4 concentrations of 20 nM and 60 nM were also tested, and no effect on the experimental results was found.

[0052] When the concentration of LPS was lower than 10 ng / mL, its effect was basically not manifested; when it was higher than 200 ng / mL, some experimental results were even inferior to those without LPS addition, including the number of goblet cells in the mouse conjunctiva and the cAMP level in the ciliary body of black-eyed rabbits, although there was no statistically significant difference between the corresponding eye drops containing exosomes B and C and the eye drops containing exosomes A (p> 0.05).

Claims

1. An eye drop composition containing stem cell exosomes, comprising exosomes from mesenchymal stem cells and a pharmaceutically acceptable carrier, wherein the exosomes are prepared by the following steps: 1) culturing the mesenchymal stem cells in a culture medium containing prostaglandin E2 and IL-4 until the cell confluence reaches 80-90%, and then performing cell subculture inoculation; 2) continuing to culture the mesenchymal stem cells after passage in a culture medium without adding prostaglandin E2 and IL-4, collecting the culture supernatant when the cell confluence is 60-70%, and separating exosomes with a diameter of 50 to 150 nm from the culture supernatant by gradient centrifugation, The concentration of prostaglandin E2 in the culture medium is 0.1-1 μM, the concentration of IL-4 in the culture medium is 20-60 nM, and the mesenchymal stem cells are human bone marrow mesenchymal stem cells.

2. The eye drop composition as claimed in claim 1, wherein lipopolysaccharide is added to the culture medium two days before the cell culture in step 1).

3. The eye drop composition as claimed in claim 2, wherein the culture medium does not contain prostaglandin E2 and IL-4 in the first two days of cell culture in step 1).

4. The eye drop composition according to claim 2 or 3, wherein the concentration of lipopolysaccharide used in the culture medium is 10-200 nM.

5. The eye drop composition according to claim 1, comprising: 5 mg / L of the exosomes, 2 g / L vitamin E and 2 g / L sodium hyaluronate, wherein the concentration of the exosomes is based on the protein concentration determined by the BrandFord method.

6. A method for preparing an eye drop composition, comprising: 1) Cultivate mesenchymal stem cells in a medium containing prostaglandin E2 and IL-4 until the cell confluence reaches 80-90%, then perform cell subculture; 2) continuing to culture the mesenchymal stem cells after passage in a culture medium without adding prostaglandin E2 and IL-4, collecting the culture supernatant when the cell confluence is 60-70%, and separating exosomes with a diameter of 50 to 150 nm from the culture supernatant by gradient centrifugation; as well as 3) mixing the exosomes with a pharmaceutically acceptable carrier, The concentration of prostaglandin E2 in the culture medium is 0.1-1 μM, the concentration of IL-4 in the culture medium is 20-60 nM, and the mesenchymal stem cells are human bone marrow mesenchymal stem cells.

7. The method of claim 6, wherein lipopolysaccharide is added to the culture medium two days before the cell culture in step 1).

8. The method of claim 7, wherein the culture medium does not contain prostaglandin E2 and IL-4 in the first two days of cell culture in step 1).

9. The method according to claim 7 or 8, wherein the lipopolysaccharide is used in the culture medium at a concentration of 10-200 nM.

Citation Information

Cited By

  • Exosome-containing eye drops as well as preparation method and application thereof

    CN120078715A

  • Water-soluble cellulose derivative-silk fibroin artificial tear with long-acting retention and non-irritating characteristics and preparation method of water-soluble cellulose derivative-silk fibroin artificial tear

    CN121371131A